» Articles » PMID: 35344670

Pathophysiological Analysis of Uninephrectomized Db/db Mice As a Model of Severe Diabetic Kidney Disease

Overview
Journal Physiol Res
Specialty Physiology
Date 2022 Mar 28
PMID 35344670
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetic nephropathy, included in diabetic kidney disease (DKD), is the primary disease leading to end-stage renal disease (ESRD) or dialysis treatment, accounting for more than 40% of all patients with ESRD or receiving dialysis. Developing new therapeutics to prevent the transition to ESRD or dialysis treatment requires an understanding of the pathophysiology of DKD and an appropriate animal model for drug efficacy studies. In this study, we investigated the pathophysiology of diabetic kidney disease with type 2 diabetes in uninephrectomized db/db mice. In addition, the nephrectomized db /db mice from 10 weeks to 42 weeks were used to assess the efficacy of long-term administration of the angiotensin-II-receptor antagonist losartan. The blood and urinary biochemical parameters, main pharmacological endpoint of the losartan therapy, were periodically measured. And at the end, histopathological analysis was performed. Uninephrectomized db/db mice clearly developed obesity and hyperglycemia from young age. Furthermore, they showed renal pathophysiological changes, such as increased urinary albumin-creatinine ratio (UACR) (the peak value 3104 ± 986 in 40-week-old mice), glomerular hypertrophy and increased fibrotic areas in the tubulointerstitial tubules. The blood pressure in the losartan group was significantly low compared to the normotensive Vehicle group. However, as expected, Losartan suppressed the increase in UACR (829±500) indicating the medication was sufficient, but the histopathological abnormalities including tubular interstitial fibrosis did not improve. These results suggest that the uninephrectomized db/db mice are useful as an animal model of the severe DKD indicated by the comparison of the efficacy of losartan in this model with the efficacy of losartan in clinical practice.

Citing Articles

Study on the Correlation Between Renal Blood Perfusion and Kidney Injury in Different Weekly-Aged Type 2 Diabetic Mice.

Wu Z, Wang X, Gao Y, Chen X, Li M, Jin X Physiol Res. 2024; 73(5):717-727.

PMID: 39530907 PMC: 11629956. DOI: 10.33549/physiolres.935405.


SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice.

Martos-Guillami N, Vergara A, Llorens-Cebria C, Motto A, Martinez-Diaz I, Goncalves F Front Pharmacol. 2024; 15:1415879.

PMID: 39434906 PMC: 11491409. DOI: 10.3389/fphar.2024.1415879.


Renal transcriptome analysis of uninephrectomized db/db mice identified a mechanism for the transition to severe diabetic nephropathy.

Maekawa M, Maekawa T, Sasase T, Wakashima T, Uemura A, Uno K Exp Anim. 2023; 73(1):29-40.

PMID: 37482420 PMC: 10877145. DOI: 10.1538/expanim.22-0168.


Unilateral nephrectomized SHR/NDmcr-cp rat shows a progressive decline of glomerular filtration with tubular interstitial lesions.

Shinozaki Y, Fukui K, Maekawa M, Toyoda K, Yoshiuchi H, Inagaki K Physiol Res. 2023; 72(2):209-220.

PMID: 37159855 PMC: 10226397.


The UDPase ENTPD5 regulates ER stress-associated renal injury by mediating protein N-glycosylation.

Xu L, Zhou Y, Wang G, Bo L, Jin B, Dai L Cell Death Dis. 2023; 14(2):166.

PMID: 36849424 PMC: 9971188. DOI: 10.1038/s41419-023-05685-4.

References
1.
Ninichuk V, Kulkarni O, Clauss S, Anders H . Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy. Eur J Med Res. 2007; 12(8):351-5. View

2.
Trevisan R, Dodesini A . The Hyperfiltering Kidney in Diabetes. Nephron. 2016; 136(4):277-280. DOI: 10.1159/000448183. View

3.
Sharma K, McCue P, Dunn S . Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol. 2003; 284(6):F1138-44. DOI: 10.1152/ajprenal.00315.2002. View

4.
Kujal P, Vernerova Z . [5/6 nephrectomy as an experimental model of chronic renal failure and adaptation to reduced nephron number]. Cesk Fysiol. 2009; 57(4):104-9. View

5.
Kim Y, Park C . Mechanisms of Adiponectin Action: Implication of Adiponectin Receptor Agonism in Diabetic Kidney Disease. Int J Mol Sci. 2019; 20(7). PMC: 6480391. DOI: 10.3390/ijms20071782. View